fren

Michael Parr, Ph.D., Director of Formulation and Process Development, Evonik

Dr. Parr has more than 20 years of experience in the pharmaceutical industry, including founding Sitka Biopharma from the Centre for Drug Research and Development (adMare), serving as President and Chief Scientific Officer. He has also served as Program Manager at Angiotech Pharmaceuticals, and also held roles supporting research, manufacturing and clinicals at Biogen-Idec in Boston. Dr. Parr’s expertise includes drug delivery systems, formulation, viral vector design, GLP, GMP activities and clinical development. Dr. Parr holds a B.Sc. Honours and Ph.D. in Biochemistry and Molecular Biology from the University of British Columbia in Vancouver, BC and completed post-doctoral studies at Harvard Medical School. He currently serves as part of the Evonik Health Care division, in the position of Director of Formulation and Process Development for the Vancouver site, responsible for leading multifunctional teams and ensuring the successful execution of a portfolio of complex customer-funded development programs as part of the Parenteral Drug Delivery Solutions business.